ECSP22021881A - Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso - Google Patents
Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su usoInfo
- Publication number
- ECSP22021881A ECSP22021881A ECSENADI202221881A ECDI202221881A ECSP22021881A EC SP22021881 A ECSP22021881 A EC SP22021881A EC SENADI202221881 A ECSENADI202221881 A EC SENADI202221881A EC DI202221881 A ECDI202221881 A EC DI202221881A EC SP22021881 A ECSP22021881 A EC SP22021881A
- Authority
- EC
- Ecuador
- Prior art keywords
- prolgolimab
- antibody
- pharmaceutical composition
- aqueous pharmaceutical
- aqueous compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a las nuevas composiciones acuosas de los anticuerpos anti-PD-1, y en particular a las nuevas composiciones acuosas del anticuerpo anti-PD-1 prolgolimab, que pueden usarse como un agente medicinal para el tratamiento de neoplasias malignas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2019126511A RU2806320C2 (ru) | 2019-08-22 | Водная фармацевтическая композиция антитела к pd-1 пролголимаба и ее применение |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22021881A true ECSP22021881A (es) | 2022-04-29 |
Family
ID=71558267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202221881A ECSP22021881A (es) | 2019-08-22 | 2022-03-22 | Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP4019047A4 (es) |
JP (1) | JP2022544850A (es) |
KR (1) | KR20220147061A (es) |
CN (1) | CN111420049A (es) |
AR (1) | AR119805A1 (es) |
AU (1) | AU2020333023A1 (es) |
BR (1) | BR112022003378A2 (es) |
CA (1) | CA3148978A1 (es) |
CO (1) | CO2022001829A2 (es) |
EC (1) | ECSP22021881A (es) |
JO (1) | JOP20220045A1 (es) |
MA (2) | MA61742A1 (es) |
MX (1) | MX2022002185A (es) |
PE (1) | PE20220932A1 (es) |
TW (1) | TW202114637A (es) |
UY (1) | UY38851A (es) |
WO (1) | WO2021034228A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3007481C (en) * | 2015-12-07 | 2024-01-30 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab |
DK3458478T3 (da) * | 2016-05-18 | 2021-03-22 | Boehringer Ingelheim Int | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling |
RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
-
2020
- 2020-04-15 TW TW109112698A patent/TW202114637A/zh unknown
- 2020-04-15 CN CN202010297418.9A patent/CN111420049A/zh active Pending
- 2020-08-21 EP EP20853868.6A patent/EP4019047A4/en active Pending
- 2020-08-21 AU AU2020333023A patent/AU2020333023A1/en active Pending
- 2020-08-21 MA MA61742A patent/MA61742A1/fr unknown
- 2020-08-21 WO PCT/RU2020/050197 patent/WO2021034228A1/ru unknown
- 2020-08-21 PE PE2022000293A patent/PE20220932A1/es unknown
- 2020-08-21 MX MX2022002185A patent/MX2022002185A/es unknown
- 2020-08-21 JO JOP/2022/0045A patent/JOP20220045A1/ar unknown
- 2020-08-21 BR BR112022003378A patent/BR112022003378A2/pt unknown
- 2020-08-21 UY UY0001038851A patent/UY38851A/es unknown
- 2020-08-21 JP JP2022512336A patent/JP2022544850A/ja active Pending
- 2020-08-21 CA CA3148978A patent/CA3148978A1/en active Pending
- 2020-08-21 KR KR1020227009582A patent/KR20220147061A/ko unknown
- 2020-08-21 MA MA56263A patent/MA56263A1/fr unknown
- 2020-08-24 AR ARP200102365A patent/AR119805A1/es unknown
-
2022
- 2022-02-21 CO CONC2022/0001829A patent/CO2022001829A2/es unknown
- 2022-03-22 EC ECSENADI202221881A patent/ECSP22021881A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA61742A1 (fr) | 2023-11-30 |
CO2022001829A2 (es) | 2022-03-29 |
CA3148978A1 (en) | 2021-02-25 |
KR20220147061A (ko) | 2022-11-02 |
AU2020333023A1 (en) | 2022-11-03 |
RU2019126511A (ru) | 2021-02-24 |
JOP20220045A1 (ar) | 2023-01-30 |
CN111420049A (zh) | 2020-07-17 |
PE20220932A1 (es) | 2022-05-31 |
MA56263A1 (fr) | 2022-11-30 |
AR119805A1 (es) | 2022-01-12 |
WO2021034228A1 (ru) | 2021-02-25 |
MX2022002185A (es) | 2022-04-20 |
JP2022544850A (ja) | 2022-10-21 |
TW202114637A (zh) | 2021-04-16 |
UY38851A (es) | 2021-02-26 |
EP4019047A1 (en) | 2022-06-29 |
RU2019126511A3 (es) | 2021-04-30 |
EP4019047A4 (en) | 2023-06-07 |
BR112022003378A2 (pt) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
CO2020005887A2 (es) | Compuestos policíclicos como inhibidores alostéricos de shp2 | |
CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
CL2018003569A1 (es) | Compuestos moduladores de fxr (nr1h4). | |
CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
UY37617A (es) | Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo | |
CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
PE20220220A1 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
BR112022002653A2 (pt) | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit de partes | |
CL2011002675A1 (es) | Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso |